Amgen (AMGN) Given News Impact Rating of 0.20
News coverage about Amgen (NASDAQ:AMGN) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amgen earned a news impact score of 0.20 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 46.5281382769207 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- New Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke (finance.yahoo.com)
- New Virtual Histology Sub-Study Evaluates Impact Of Repatha® (Evolocumab) On Coronary Artery Plaque Composition (finance.yahoo.com)
- How Did Pfizer Perform in 2Q17? (finance.yahoo.com)
- Ameriprise Financial Inc. Has $242.56 Million Stake in Amgen Inc. (AMGN) (wisdomsave.com)
- Just the Facts on Amgen Inc. (AMGN) (techkenyot.com)
Amgen (AMGN) traded up 0.26% during mid-day trading on Tuesday, hitting $172.23. 1,483,019 shares of the stock were exchanged. Amgen has a 52 week low of $133.64 and a 52 week high of $184.21. The stock has a market cap of $125.67 billion, a price-to-earnings ratio of 15.69 and a beta of 1.35. The company has a 50 day moving average price of $173.53 and a 200 day moving average price of $168.31.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period last year, the firm posted $2.84 EPS. Analysts expect that Amgen will post $12.57 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be issued a dividend of $1.15 per share. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 annualized dividend and a yield of 2.67%. Amgen’s payout ratio is currently 41.93%.
AMGN has been the topic of several analyst reports. Cann reaffirmed a “buy” rating on shares of Amgen in a research note on Monday. Deutsche Bank AG assumed coverage on shares of Amgen in a research note on Friday, June 23rd. They set a “hold” rating and a $172.00 price target on the stock. Oppenheimer Holdings, Inc. set a $189.00 price objective on shares of Amgen and gave the stock a “buy” rating in a report on Monday, June 5th. ValuEngine lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, William Blair reiterated a “market perform” rating on shares of Amgen in a report on Monday, June 26th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $186.04.
COPYRIGHT VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/amgen-amgn-given-news-impact-rating-of-0-20/1530438.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.